Veeral Desai - 19 Apr 2022 Form 4 Insider Report for agilon health, inc. (AGL)

Role
Chief Strategy & Dev. Officer
Signature
/s/ Lyn Amor Macaraeg, as Attorney-in-Fact
Issuer symbol
AGL
Transactions as of
19 Apr 2022
Net transactions value
-$4,581,860
Form type
4
Filing time
21 Apr 2022, 16:05:09 UTC
Previous filing
29 Sep 2022
Next filing
25 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGL Common Stock Options Exercise $106,357 +106,357 +38% $1.00* 384,568 19 Apr 2022 Direct F1
transaction AGL Common Stock Sale $2,418,558 -106,357 -28% $22.74 278,211 19 Apr 2022 Direct F1, F2, F3
transaction AGL Common Stock Options Exercise $106,357 +106,357 +38% $1.00* 384,568 20 Apr 2022 Direct F1
transaction AGL Common Stock Sale $2,376,015 -106,357 -28% $22.34 278,211 20 Apr 2022 Direct F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGL Options (Rights to Buy) Options Exercise $0 -106,357 -12% $0.000000 775,351 19 Apr 2022 Common Stock 106,357 $1.00 Direct F5
transaction AGL Options (Rights to Buy) Options Exercise $0 -106,357 -14% $0.000000 668,994 20 Apr 2022 Common Stock 106,357 $1.00 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes restricted stock units.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $21.90 to $23.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $21.76 to $22.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 These options were granted on April 27, 2017 and fully vested on April 27, 2021.